Shanghai Pharmaceuticals Holding (02607): Prilbaylin Capsules Obtained Drug Registration Certificate in the Philippines.

16:39 27/02/2026

Shanghai Pharmaceuticals (02607) announced that recently, Pruvaberine capsules produced by its subsidiary Changzhou Pharmaceutical Factory Limited have received a drug registration certificate from the Food and Drug Administration of the Philippines, and the drug has been approved for listing.

Shanghai Pharmaceuticals Holding (02607) announced that recently, the pregabalin capsules produced by its subsidiary Changzhou Pharmaceutical Factory Limited have received a drug registration certificate from the Philippines Food and Drug Administration, allowing the drug to be approved for market launch. Pregabalin capsules are mainly used for the treatment of post-herpetic neuralgia, diabetic peripheral neuropathy, fibromyalgia, neuropathic pain caused by spinal cord injury, and as an adjunctive therapy for epilepsy. This time, pregabalin capsules in three specifications (50mg, 75mg, 150mg) have obtained the drug registration approval from the Philippines Food and Drug Administration, marking the company's qualification to sell the drug in the Philippines market. This will have a positive impact on the company's expansion into overseas markets and will accumulate valuable experience.

WAI CHUN BIOTEC (00660) releases its interim performance, with a net loss attributable to shareholders of HK$5.939 million, a decrease of 56.53% compared to the same period last year.

China Motor Bus (00026) released its interim results, with a post-tax loss attributable to shareholders of HK$64.404 million, representing an 88.29% increase year-on-year.

HAOHAI BIOTEC (06826) is expected to have a net profit attributable to the parent company of approximately 2.51 billion yuan in 2025, a decrease of 40.3% year-on-year.

WAI CHUN BIOTEC (00660) releases its interim performance, with a net loss attributable to shareholders of HK$5.939 million, a decrease of 56.53% compared to the same period last year.

China Motor Bus (00026) released its interim results, with a post-tax loss attributable to shareholders of HK$64.404 million, representing an 88.29% increase year-on-year.

HAOHAI BIOTEC (06826) is expected to have a net profit attributable to the parent company of approximately 2.51 billion yuan in 2025, a decrease of 40.3% year-on-year.